Sansure Biotech Inc., now a listed company in China, established in 2008, is an integrated solution provider with independent innovating molecular diagnostics and gene technology, has over 10-year experience specialized in diagnostic reagents, nucleic acid diagnostic instruments, complete lab solutions and lab chain services. Sansure solutions for molecular diagnosis are compatible with majority of PCR detection instruments and lab environments based on unique technical platforms “global leading magnetic beads extraction system”, “one of the simplest and fastest one-step DNA/RNA lysis systems”, automated nucleic acid extraction system, POCT devices and real-time PCR instruments. Over 40% of its employees work for R&D and technical service departments, over one hundred of products with global registrations, including infectious diseases, cancer, maternal and children health, blood screening, emerging infectious diseases prevention and control, chronic disease management, etc.

On August 28, 2020, SANSURE BIOTECH (Stock Code: 688289) was listed on the science and Technology Innovation Board of Shanghai Stock Exchange.